Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Margitta Retz

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
The Lancet. Oncology|January 30, 2017
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialPadmanee Sharma, Margitta Retz, Arlene Siefker-Radtke, et al.
European Urology|November 3, 2012
Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programmeAxel Heidenreich, Hans-Jörg Scholz, Sebastian Rogenhofer, et al.
Urologic Oncology|May 17, 2023
Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trialJulia Heinzelbecker, Natalie Spieler, Michael Kuehn, et al.
European Urology|October 20, 2018
Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized TrialJürgen E Gschwend, Matthias M Heck, Jan Lehmann, et al.
European Urology Oncology|February 26, 2026
Radiation Therapy Combined with Immunotherapy Before Radical Cystectomy in Locally Advanced Bladder Cancer: A Prospective, Single-arm, Multicenter, Phase 2 Trial (RACE-IT)Sebastian C Schmid, Matthias Jahnen, Kilian Schiller, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2021
Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trialKarim Fizazi, Pablo González Mella, Daniel Castellano, et al.
European Urology|September 18, 2025
Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph Node Dissection in Patients with Bladder Cancer Undergoing Radical CystectomyMatthias Michael Heck, Jan Lehmann, Thomas Amiel, et al.
European Urology|December 9, 2008
Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05)Jan Lehmann, Henrik Suttmann, Peter Albers, et al.
European Urology Focus|June 5, 2024
Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract CarcinomaCora N Sternberg, Yohann Loriot, Ernest Choy, et al.
European Urology Oncology|November 8, 2023
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 StudyEvan Y Yu, William R Berry, Howard Gurney, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
The Lancet. Oncology|January 30, 2017
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialPadmanee Sharma, Margitta Retz, Arlene Siefker-Radtke, et al.
European Urology|November 3, 2012
Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programmeAxel Heidenreich, Hans-Jörg Scholz, Sebastian Rogenhofer, et al.
Urologic Oncology|May 17, 2023
Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trialJulia Heinzelbecker, Natalie Spieler, Michael Kuehn, et al.
European Urology|October 20, 2018
Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized TrialJürgen E Gschwend, Matthias M Heck, Jan Lehmann, et al.
European Urology Oncology|February 26, 2026
Radiation Therapy Combined with Immunotherapy Before Radical Cystectomy in Locally Advanced Bladder Cancer: A Prospective, Single-arm, Multicenter, Phase 2 Trial (RACE-IT)Sebastian C Schmid, Matthias Jahnen, Kilian Schiller, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2021
Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trialKarim Fizazi, Pablo González Mella, Daniel Castellano, et al.
European Urology|September 18, 2025
Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph Node Dissection in Patients with Bladder Cancer Undergoing Radical CystectomyMatthias Michael Heck, Jan Lehmann, Thomas Amiel, et al.
European Urology|December 9, 2008
Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05)Jan Lehmann, Henrik Suttmann, Peter Albers, et al.
European Urology Focus|June 5, 2024
Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract CarcinomaCora N Sternberg, Yohann Loriot, Ernest Choy, et al.
European Urology Oncology|November 8, 2023
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 StudyEvan Y Yu, William R Berry, Howard Gurney, et al.
Pageof 10